Physician profile
Tracy B Evans
NPI 1548427875
$18,358.07
in general payments reported to CMS, 2019-2025
33 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,112 · 2020: $3,316 · 2021: $2,478 · 2022: $2,438 · 2023: $2,086 · 2024: $1,584 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,898 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,898.25 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $6,581.21 | 2019-2025 | Xeomin |
| Allergan, INC. | $2,285.42 | 2019-2022 | |
| Pfizer INC. | $1,735.25 | 2019-2025 | |
| Leo Pharma INC. | $1,610.16 | 2019-2024 | Adbry |
| Mayne Pharma Commercial LLC | $865.29 | 2019-2021 | |
| Abbvie INC. | $861.29 | 2021-2025 | |
| Galderma Laboratories, L.P. | $487.11 | 2019-2025 | Nemluvio |
| Amgen INC. | $374.87 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $347.88 | 2020-2025 | |
| Revance Therapeutics, INC. | $345.68 | 2024-2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $321.04 | 2019-2025 | Libtayo, Dupixent |
| Organon LLC | $274.41 | 2025 | Vtama |
| Janssen Biotech, INC. | $258.41 | 2020-2023 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $252.74 | 2021-2024 | Bimzelx |
| Solta Medical, A Division of Bausch Health US, LLC | $223.85 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $199.96 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $184.85 | 2024-2025 | Zoryve |
| Incyte Corporation | $181.22 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $176.00 | 2020-2024 | Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $133.43 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $122.84 | 2023-2025 | Winlevi, Absorica Ld |
| Biofrontera INC. | $100.78 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Dermira, INC. | $86.59 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $67.47 | 2020 | |
| Organogenesis INC. | $57.70 | 2021-2024 | |
| Journey Medical Corporation | $41.33 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.13 | 2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $35.43 | 2020 | |
| Tersera Therapeutics LLC | $23.61 | 2024 | Zoladex |
| Almirall LLC | $22.92 | 2019 | |
| Epi Health, LLC | $21.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.30 | 2024 | Ninlaro |
| Genentech USA, INC. | $19.29 | 2023 | Phesgo, Perjeta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.